{"links":{"feed":"https://www.erudio.com/reports/liger-hn1-nct06525220/feed.json","html":"https://www.erudio.com/reports/liger-hn1-nct06525220","json":"https://www.erudio.com/reports/liger-hn1-nct06525220.json","markdown":"https://www.erudio.com/reports/liger-hn1-nct06525220.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"liger-hn1-nct06525220"}},"request":"https://www.erudio.com/contact?report=liger-hn1-nct06525220"},"offer":{"cited_clinicians":6,"cited_commentary_sources":35,"verified_hcp_statements":321,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified speaker identities: the verified IDs of the people in the report, led by the NPI or their institution's staff page, so a Medical Affairs team can check that each statement is attributed to the right person: also X, Bluesky, LinkedIn and other web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For checking attribution inside the organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":1950,"identity_verified_people":6,"optional":true,"price_per_verified_person_usd":15,"price_usd":90,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":1950,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or 3, 6 or 12 months of updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"liger-hn1-nct06525220"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=liger-hn1-nct06525220","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/liger-hn1-nct06525220","renewal":"Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"deep","size_line":"Deep · 321 verified statements · 182 from 6 confirmed clinicians","size_rule":"Deep: 301+ verified statements. Standard and Deep need 5 or more confirmed clinicians cited (role verified by the NPI registry or their own institution's staff page); otherwise a report is Focused.","updates_usd":{"3_months":3400,"6_months":4900,"12_months":6800},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-11-08T22:02:25.562662Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":14,"no_commentary_found":0},"aspects":[{"claim_count":17,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":8,"title":"Primary endpoint: Overall Survival (OS)"},{"claim_count":14,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":6,"title":"Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)"},{"claim_count":7,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":7,"title":"Secondary endpoints"},{"claim_count":29,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":8,"title":"Population and setting"},{"claim_count":31,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":13,"title":"The comparison"},{"claim_count":14,"coverage":"discussed","id":"T6","registry_field":"outcomesModule","source_count":9,"title":"Safety and tolerability"},{"claim_count":11,"coverage":"discussed","id":"T7","registry_field":"designModule","source_count":6,"title":"Design and conduct"},{"claim_count":17,"coverage":"discussed","id":"A1","source_count":5,"title":"Biological rationale and earlier clinical evidence"},{"claim_count":22,"coverage":"discussed","id":"A2","source_count":5,"title":"Biomarker work-up and limits of treatment-selection shortcuts"},{"claim_count":19,"coverage":"discussed","id":"A3","source_count":3,"title":"Salvage feasibility and the local-versus-systemic decision"},{"claim_count":22,"coverage":"discussed","id":"A4","source_count":3,"title":"Upfront intensification, post-progression treatment and sequencing"},{"claim_count":19,"coverage":"discussed","id":"A5","source_count":5,"title":"Administration, supportive care and multidisciplinary readiness"},{"claim_count":37,"coverage":"discussed","id":"A6","source_count":12,"title":"Competitive evidence thresholds and conditional development consequences"},{"claim_count":5,"coverage":"discussed","id":"A100","source_count":1,"title":"Frontline treatment-selection context from HNSCC: Current and Emerging Therapeutic Strategies"}],"counts":{"beyond_population_findings":2,"cited_clinicians":6,"cited_clinicians_by_role":{"physician":3,"physician, Medical oncology":2,"physician, Surgical oncology":1},"cited_physicians":6,"cited_sources":37,"claims_by_expression_type":{"comparison":33,"experience":19,"interpretation":80,"opinion":83,"primary_context":6,"question":12,"restatement":44,"uncertainty":21,"unspecified":23},"claims_by_kind":{"interpretation":1,"protocol_statement":2,"publication_statement":6,"source_observation":312},"clinician_statements":182,"evidence_units":172,"findings":8,"organisational_accounts":9,"people_cited":16,"people_identity_verified":6,"people_total":16,"screened_sources":76,"verified_claims":321},"findings_index":[{"cited_clinicians":1,"id":"F1","structure":{"claims":9,"claims_by_group":{"comparisons":2,"experience":0,"questions":1,"restated":0,"views":6},"limitations":2,"links":{"context":1,"support":11},"ma_question":true,"named_voices":2,"passages":9,"sources":9,"sources_by_kind":{"commentary":9}},"title":"Commentators welcome the survival signal; one clinician asks how it compares with pembrolizumab plus chemotherapy"},{"cited_clinicians":4,"id":"F2","structure":{"claims":33,"claims_by_group":{"comparisons":1,"experience":4,"questions":2,"restated":2,"views":24},"limitations":4,"links":{"context":5,"support":37},"ma_question":true,"named_voices":4,"passages":20,"sources":5,"sources_by_kind":{"media":5}},"title":"Clinicians condition trial consideration on resectability; one favors a chemotherapy-containing control for high symptom burden"},{"cited_clinicians":3,"id":"F3","structure":{"claims":19,"claims_by_group":{"comparisons":5,"experience":0,"questions":0,"restated":3,"views":11},"limitations":4,"links":{"context":0,"support":20},"ma_question":true,"named_voices":3,"passages":12,"sources":6,"sources_by_kind":{"commentary":1,"media":5}},"title":"Clinicians welcome early EGFR activity; one makes future first-line use conditional on phase III confirmation"},{"cited_clinicians":4,"id":"F4","structure":{"claims":27,"claims_by_group":{"comparisons":3,"experience":0,"questions":10,"restated":3,"views":11},"limitations":5,"links":{"context":5,"support":28},"ma_question":true,"named_voices":7,"passages":15,"sources":7,"sources_by_kind":{"commentary":4,"media":3}},"title":"Speakers and accounts seek HPV detail; one account predicts reliable efficacy only in HPV-negative disease"},{"cited_clinicians":0,"id":"F5","structure":{"claims":31,"claims_by_group":{"comparisons":6,"experience":0,"questions":6,"restated":6,"views":13},"limitations":4,"links":{"context":1,"support":32},"ma_question":true,"named_voices":2,"passages":8,"sources":7,"sources_by_kind":{"commentary":7}},"title":"Accounts credit the survival endpoint but say the absolute benefit cannot yet be sized"},{"cited_clinicians":2,"id":"F6","structure":{"claims":16,"claims_by_group":{"comparisons":6,"experience":0,"questions":1,"restated":3,"views":6},"limitations":5,"links":{"context":1,"support":19},"ma_question":true,"named_voices":2,"passages":14,"sources":9,"sources_by_kind":{"commentary":4,"media":4,"publication":1}},"title":"One clinician regards infusion reactions as manageable while stressing administration precautions and schedule differences"},{"cited_clinicians":4,"id":"F8","structure":{"claims":15,"claims_by_group":{"comparisons":0,"experience":1,"questions":5,"restated":2,"views":7},"limitations":4,"links":{"context":2,"support":16},"ma_question":true,"named_voices":4,"passages":10,"sources":5,"sources_by_kind":{"media":4,"registry":1}},"title":"One clinician conditionally favors upfront EGFR combinations; another asks whether response and PFS gains translate into lasting benefit"},{"cited_clinicians":0,"id":"F9","structure":{"claims":37,"claims_by_group":{"comparisons":8,"experience":0,"questions":0,"restated":3,"views":26},"limitations":5,"links":{"context":1,"support":43},"ma_question":true,"named_voices":4,"passages":16,"sources":12,"sources_by_kind":{"commentary":12}},"title":"Accounts offer differing, conditional readings of competing development routes"}],"open_question":{"basis":"From finding F1 (9 statements from 2 speakers in 9 sources)","cited_claim_ids":["claim-0b8c694d23bfd5f3530f","claim-22abce339e5d33e86836","claim-75fff95b54e76ce21acb","claim-0efd8de935d542a9b917","claim-49245fde88adc12c4b84","claim-9e737aed97a53bf9b34a","claim-ff841365082d1357a8f6"],"finding_ids":["F1"],"question":"What do clinicians still need to see to compare petosemtamab plus pembrolizumab with pembrolizumab plus chemotherapy in first-line PD-L1-positive recurrent or metastatic HNSCC, given LiGeR-HN1’s pembrolizumab-alone control?"},"sections":{"analysis":[{"id":"section-1","level":2,"title":"Welcoming survival evidence without answering every first-line comparison"},{"id":"section-2","level":2,"title":"Trial suitability depends on local-treatment options, symptoms and access"},{"id":"section-3","level":2,"title":"Early activity explains enthusiasm, not a retrospective phase III result"},{"id":"section-4","level":2,"title":"HPV applicability remains contested rather than resolved by the pooled result"},{"id":"section-5","level":2,"title":"Relative-effect confidence does not establish absolute magnitude or maturity"},{"id":"section-6","level":2,"title":"Manageable reactions still carry treatment and administration burden"},{"id":"section-7","level":2,"title":"Supportive care remains part of treatment selection and trial fitness"},{"id":"section-8","level":2,"title":"Upfront intensification remains conditional, and the long-term sequencing question stays open"},{"id":"section-9","level":2,"title":"Beyond the trial population"},{"id":"section-10","level":3,"title":"Competitive development readings are conditional and conflicting"},{"id":"section-11","level":3,"title":"Later-line options are discussed as pathways, not validated sequences"},{"id":"section-12","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":2},{"id":"F5","shared_claims":15},{"id":"F6","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T1","label":"Primary endpoint: Overall Survival (OS)"},{"findings":[{"id":"F5","shared_claims":14}],"id":"T2","label":"Primary endpoint: Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":4},{"id":"F6","shared_claims":1},{"id":"F8","shared_claims":1}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":3},{"id":"F4","shared_claims":19},{"id":"F8","shared_claims":1},{"id":"F9","shared_claims":1}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":5},{"id":"F2","shared_claims":15},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1},{"id":"F9","shared_claims":2}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F5","shared_claims":3},{"id":"F6","shared_claims":12},{"id":"F9","shared_claims":1}],"id":"T6","label":"Safety and tolerability"},{"findings":[{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":8},{"id":"F9","shared_claims":2}],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-11-08T22:02:25.562662Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-11-09T00:59:26Z","record_hash":"17811615dd106171858878645fa612ad463b25b9933fed4af24fdc1cc68bbf39","release_hash":"bf5c3b240be60d0a85cbe7a605402ecd4b70bcfb1556960dac9cd47bf9b33325","report_id":"erudio-nct06525220","run_id":"0a0014ee-e0c1-437b-ba70-86162b4e3b98","schema_version":"5.0","slug":"liger-hn1-nct06525220","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"A surgical oncologist reads LiGeR-HN1 favorably because of the reported size of its survival effect, but questions its position alongside pembrolizumab plus chemotherapy. In earlier treatment-selection context, the clinicians cited weigh symptoms and PD-L1 CPS; one medical oncologist considers monotherapy reasonable for low symptom burden when minimizing toxicity is a priority. Full results remain awaited to clarify absolute survival gains, HPV-specific effects and adverse-event rates.","examples":[{"claim_id":"claim-496a604f0514273f58f0","finding_id":"F2","identity_check":"staff_page","month":"2026-07","region":"ex-US","role":"Physician","source_type":"podcast","statement":"sees a good opportunity to offer pembrolizumab plus a non-chemotherapy drug, particularly because the tumor is oral cavity and p16 negative, a disease profile they believe could potentially benefit from EGFR-targeted therapy."},{"claim_id":"claim-d8c238c92b61a9b23389","finding_id":"F3","identity_check":"npi_registry","month":"2026-05","region":"US","role":"Physician","source_type":"podcast","statement":"considers emerging anti-EGFR strategies particularly exciting for HPV-negative disease, describing a foundation of studies combining cetuximab with pembrolizumab or nivolumab that showed better response rates and progression-free survival than historical pembrolizumab controls, particularly in HPV-negative patients."},{"claim_id":"claim-54bdb8f49ab6c1403459","finding_id":"F4","identity_check":"npi_registry","month":"2026-03","region":"US","role":"Medical oncologist","source_type":"podcast","statement":"awaits the phase III petosemtamab findings in HPV-positive disease."}],"meta_description":"76 sources screened · 321 verified statements (182 from clinicians verified by NPI or staff page) from 37 sources · 8 findings. Updated Nov 8, 2026.","person_names_policy":"role_only"},"publication":{"approved_at":"2026-11-09T00:59:26Z","approved_by":"Erudio publisher","corrections":[{"affected_ids":[],"date":"2026-11-09T00:59:26Z","kind":"routine","summary":"The trial's name is spelled as its investigators write it, “LiGeR-HN1” (NCT06525220), outside quotations (was “LEGER”, “LIGAR”, “LIGER”, “LIGHER”, “Liger”)."}],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":76},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on uncertain disease-control benefits of an alternative pembrolizumab combination in HPV-negative head and neck cancer; a view on dissent and anecdotal evidence when weighing immunotherapy doublets against single-agent treatment.","2 more clinician views in the sources used in this report are not yet captured as evidence in this edition.","1 passage in 1 source used in this report was not fully assessed for clinician views, so a view there may be missing from this edition.","169 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: 15 sources about other trials or topics are not included; discussion that uses 3 names the trial shares with other things, without the trial's condition or setting, may be missing.","The sources reviewed for this edition are not a representative sample of HCP opinion. Social accounts, analyst relays and company-announcement summaries must not be counted as independently confirmed clinical consensus.","Repeated podcast/video versions and near-identical posts can represent the same discussion or author rather than additional independent agreement.","Discussion that does not name the trial or uses different transcription variants may be missing. One additional passage was not fully assessed, and a separate passage could not support a named attribution.","Some passages cannot be assigned to a named speaker. They remain commentary from the relevant discussion and cannot establish agreement or disagreement between additional people.","Clinical roles for several named social authors and accounts are unknown or unconfirmed. A source's description of someone as MD is attributed source wording, not independent confirmation.","Phase III results discussed here are company-reported topline information relayed through commentary. Arm-level absolute outcomes, follow-up, event counts, detailed safety and quantitative subgroup results remain necessary for a fuller reading.","Earlier phase II cohorts, later-line monotherapy findings, historical controls and personal numerical estimates cannot be substituted for LiGeR-HN1 outcomes or direct comparisons.","No registry protocol file or exact product labels were available to check every design or approval description. The journal protocol describes planned methods rather than observed phase III results.","Publication, post and repost dates do not establish a session date, a readout presentation date or a speaker's change of mind.","Some connected discussion is incomplete: HPV-negative interpretations and an HPV-positive biological hypothesis for INBRX-106, the full alternative-agent durability comparison, an alternative combination's population-specific biological rationale, an episode's precise eligibility wording, and qualifications concerning immunotherapy after PD-1 failure are not fully represented. These summaries should not be treated as complete accounts of those exchanges."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":1,"other":0,"podcast":3,"publication":1,"registry":1,"regulatory":0,"x_thread":28,"x_video":0,"youtube":3},"by_evidence_role":{"commentary":35,"methods":2},"count":37,"evidence_window":{"end":"2026-11-02","start":"2024-12-02"},"retrieval_snapshot":"2026-11-08T20:41:18.645019Z","timeline":[{"count":2,"week":"2024-W49"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W11"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W28"},{"count":22,"week":"2026-W44"},{"count":4,"week":"2026-W45"}],"undated_sources":2},"quote_policies":[{"id":"clinicaltrials:NCT06525220:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT06525220:context","quote_policy":"short_quote_link_out"},{"id":"pubmed:40511820","quote_policy":"no_derivatives"},{"id":"mcp:bluesky_thread:plc-7sx4xfvdi6ayikr76lbjpn4p-3mz53xktzqs2b","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-b6or56vkmhywvtt2wkcsnbsc-3myxkbt77vk2x","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-hxjzi7mnsedfpxcz7ebinndv-3l5feqc7y6z2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-iezrpygpuxkzommva52xzbun-3myxqzhattz2q","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-kwntu4mgap2otpkyzq5bchim-3mywvkdgksp2s","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-r72b3lyasdsbnwi57f7qdlol-3mywzjangoa2y","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-t5kvjzece3qgysdmwvem36xv-3myxomjnq4b2f","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-vvidntidrwdocqgjy5gz2kzc-3mywwufatyc2p","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7311069138922147840","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7521668325278466048","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:41a13b","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:5ddaa0","quote_policy":"short_quote_link_out"},{"id":"mcp:podcast:f76fb7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840723408507584590:4564dda1-e4b0-40d1-8b3f-fd2dcff28dc7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840724291957969014:b361f809-c527-4c5d-ac97-53d10980dbc3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840725593480183938:b6a5d5a6-83b1-4cc3-9000-0fd80d3c2d5a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840756176041955333:a0cece7c-0874-453e-af42-3bbbca2cef49","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840814125556900234:39d1cc4a-b0f1-473e-9903-fd59c0233b03","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1840934856324211094:1ccf84bd-0c5f-4856-acf5-dd1dd1ab2454","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1841101666352869470:e1a64d33-1c2f-4398-b7c1-b8ef8fe216c7","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1863664633724170324:75d792db-837f-48b8-9b5e-7f42f5d4f028","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1863667073056211279:6fb1e104-f713-4a46-a296-49dfffbef2d3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1932122537108160732:db4ede88-f560-4ea8-9053-c319fe31ae59","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1967666869751472607:1b4daf07-e39e-483f-a231-c8c2ca09c46f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2000740283970113881:48c38fe6-b252-41e8-88dd-2011d1df089b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2001994210774487226:79357d10-28fb-4d63-b9b0-53415acb7bfc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114691296816509379:1e0b4ea1-7e4d-4b0f-a0e5-8a390610dbb4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115438798825759183:5e8ebae8-7065-4118-b207-15885fe7f25f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115439324867215379:2e46c483-4cd7-4d0c-bea4-a95665935167","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115440307663704403:033a50e4-3ac8-4232-84eb-542b0929c090","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115442979674390898:750e22c8-4132-468f-94c5-c01d562bbe77","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115447537813327925:aec2b148-ccb6-4767-9b77-31bca90efaaf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115447574358552880:b4850fa8-069b-4643-96e4-5158db3e9379","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115449010471199099:6a08fe86-bc9e-4a29-ad15-0ad71bfa50e4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115455798323147237:a8bb6f08-4353-4116-9fdc-e4580847be0b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115456275232313563:ba3d5f5f-6565-4598-bf8e-b192d6dc8c8e","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115457767523897440:d4994729-5b6e-48d7-892f-d4248217e3fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115461893859270887:f46b69bf-5596-46e6-9384-b1a2bcbaab6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115467800273711238:1eaf108c-0499-497f-9b50-43a994bd9092","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115470793820004836:cb27c4d6-27b5-4446-96ec-c7aa6cf7ffd4","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115473859113546153:3977e90e-b3c6-494a-b582-5d0e54a04331","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115498960181997694:11ded962-cfcf-4b95-b5f2-ee66fa4a81ff","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115503246550999306:68ba4494-5840-40ce-8c74-0e3597792266","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115523223383384355:909396e0-b984-4a4c-a045-e085a3f69f62","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115528258251030881:f15d2d2d-5c93-40b6-93ab-1ba784add335","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115534641733976425:dcdfcdcd-c0b8-471d-a1a5-09691630aa3b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115534974761959533:211277a5-a7dc-438f-b93d-8932f1932b76","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115554745763193092:4d93c7bd-15ef-4e5a-a2ca-cbd2e4c2a37a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115557714558673374:b7ff471a-1afd-499a-a4a6-5221b792b822","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115590034061418558:62e75ce1-2fd1-4a28-85b0-ac7e4f4b2639","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115688349100920943:df70b430-78bc-4175-aa2c-cf9ede8daf97","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115710684553949293:fbc9da7f-7c2f-4d34-970c-efc078769c7d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115761008451145822:5dc42df7-c47a-4abe-ad52-f14cbb89d26d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115816185044287573:0d8e85a7-523d-4a3c-a730-81c683ad327d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115841873936044195:17ab90ec-c625-41fb-a4f4-6ec94fe8011b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115849330108289202:4e5ded7f-0f1e-47ce-82de-dd4227161f8b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115849456969241078:d7873b88-5839-4bf2-b6cb-66e4c21abe80","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115849816563708179:1fd70629-0a58-4e5e-b227-670d1a342ce0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115849919156334920:14355244-c4f1-444f-a336-85bd7f41eaa3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115868228987568307:25da9833-bcbf-4a45-a183-26851cec51ad","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2115920423011651765:2d2d372a-ab42-4d4d-91bb-7f850b1029cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116274037936836673:88f0af5c-6fb3-45ec-aa84-bd883871542a","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116292871179661375:1dc33558-46e4-4533-9a7c-51824e33c4cb","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116349790246330762:b24e60a7-bb9a-4100-9b0f-03329b7614a3","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116570858860748867:b2ebf534-81bb-42dd-b440-a745292bd830","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116705100299112544:2a964e22-04f4-4bb0-aa48-2e9144adf4e9","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2116916850277724506:765fd1da-0029-40c8-be58-ee26fdb82b5f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117187801686925703:245874a5-3a45-4aa5-9a0b-747c4631cc16","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117273409524773034:45e38a07-cf7b-41d8-9c10-edd172619fcf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2117345106999304575:98f1ec02-a468-4e6f-ac88-48bf40a953d8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118503513760362634:8e936d62-1ce1-43bd-9e93-fa370426bcb6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2118769936407347617:59b94846-a3f3-422d-83be-c8df9361ecf5","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:BZNInwRDik4","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:SfPRPVb3qPU","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:VuDdxDnNCxY","quote_policy":"short_quote_link_out"},{"id":"mcp:youtube:gca3JpGVras","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":8,"linkedin_post":2,"other":0,"podcast":3,"publication":0,"registry":0,"regulatory":0,"x_thread":59,"x_video":0,"youtube":4},"by_evidence_role":{"commentary":76},"count":76,"evidence_window":{"end":"2026-11-06","start":"2024-09-30"},"retrieval_snapshot":"2026-11-08T20:41:18.645019Z","timeline":[{"count":8,"week":"2024-W40"},{"count":2,"week":"2024-W49"},{"count":1,"week":"2025-W13"},{"count":1,"week":"2025-W24"},{"count":1,"week":"2025-W38"},{"count":2,"week":"2025-W51"},{"count":1,"week":"2026-W08"},{"count":1,"week":"2026-W09"},{"count":1,"week":"2026-W11"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W28"},{"count":50,"week":"2026-W44"},{"count":6,"week":"2026-W45"}],"undated_sources":0},"statements_by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":123,"publication":7,"registry":1,"regulatory":0,"x_thread":110,"x_video":0,"youtube":78}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"congresses":{"reason":"No congress places this trial yet.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: petosemtamab","status":"unmapped"},{"brand_names":["Keytruda"],"label":"pembrolizumab","slug":"pembrolizumab"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Head and neck squamous cell carcinoma","slug":"head-and-neck-squamous-cell-carcinoma"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"LiGeR-HN1","aliases":["LiGeR-HN1","LiGeR - HN1","A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)","A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma"],"brief_title":"A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Head and Neck Squamous Cell Carcinoma"],"display_condition":"first-line PD-L1+ recurrent or metastatic HNSCC","display_interventions":[["petosemtamab","pembrolizumab"]],"enrollment":{"count":699,"type":"ACTUAL"},"interventions":[{"name":"Petosemtamab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pembrolizumab","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT06525220","official_title":"A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Recurrent or Metastatic PD-L1+ Head and Neck Squamous Cell Carcinoma","overall_status":"ACTIVE_NOT_RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-01","type":"ESTIMATED"},"primary_endpoints":[{"measure":"Overall Survival (OS)","timeFrame":"Up to approximately 3 years"},{"measure":"Objective Response Rate (ORR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 as assessed by blinded independent central review (BICR)","timeFrame":"Up to approximately 2 years"}],"registered_date":{"date":"2024-07-29","type":"ACTUAL"},"registry_last_updated":"2026-11-02","registry_url":"https://clinicaltrials.gov/study/NCT06525220","short_name":"LiGeR-HN1","short_name_basis":"canonical_name","sponsor":"Genmab","start_date":{"date":"2024-09-25","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"MCLA-158-CL03 (GCT1158-03)","type":"sponsor_study_id"},{"id":"2023-510323-30-00","type":"ctis"}],"study_type":"INTERVENTIONAL"}}}